Vir Biotechnology : 20th Annual Needham Healthcare Conference Presentation

The image part with relationship ID rId2 was not found in the file.

with relationship ID rId2 was not found in the file.

A WORLD WITHOUT

INFECTIOUS DISEASE

Vir Biotechnology, Inc.

20th Annual Needham Healthcare Conference

April 13, 2021

1

Legal disclaimers

Forward-Looking Statements

Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the expected success, cost, and timing of our research and clinical development plans and clinical trials, our goals with respect to the prophylaxis or treatment of COVID-19, HBV, influenza A and HIV, our objectives, strategy, technology platform and clinical trial designs, the potential benefits of our collaborations, and our ability to complete certain milestones. Words such as "believe," "anticipate," "plan," "expect," "intend," "will," "may," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the management of Vir Biotechnology, Inc. (the "Company") as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the Company, including, without limitation, risks inherent in developing the Company's products and technologies, future results from the Company's ongoing and planned clinical trials such as unexpected data or clinical site activation rates or clinical trial enrollment rates that are lower than expected, difficulties arising from our collaborations, challenges in accessing adequate manufacturing capacity, the Company's ability to obtain adequate financing to fund its planned clinical trials and other expenses, trends in the industry, changes in the competitive landscape, delays or disruptions due to the COVID-19 pandemic, the legal and regulatory framework for the industry, unexpected litigation or disputes and future expenditures. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. Other factors that may cause the Company's actual results to differ from current expectations are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including the section titled "Risk Factors" contained therein. These forward-looking statements should not be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such forward-looking statements have been made are correct or exhaustive or, in the case of the assumptions, fully stated in this presentation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this presentation is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. The Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 for all forward-looking statements.

This presentation discusses product candidates that are under clinical study and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

© 2021 Vir Biotechnology, Inc.

2

Taking on the most serious infectious diseases

Clinically validated product candidates

Applying learnings to broad ID pipeline

Potential significant near-term value drivers

© 2021 Vir Biotechnology, Inc.

3

Clinically validated antibodies

Ebola

COVID-19

HBV

Flu

mAB114*: approved for therapy; as effective as three-antibody cocktail from Regeneron

VIR-7831: 85% reduction in hospitalization or death; covers all known variants**

VIR-3434: mean 1.3 log10 drop in HBsAg after single 6 mg dose

VIR-2482:pan-influenza A with 58-dayhalf-life***;pan-influenza (A+B) in development

*Marketed as Ebanga by Ridgeback Biotherapeutics LP **Based on preclinical data

***Based on preliminary clinical data

COVID-19: coronavirus disease 2019

HBV: hepatitis B virus© 2021 Vir Biotechnology, Inc.4

HBsAg: hepatitis B virus surface antigen

Antibody engineering technologies

LS mutation

• Licensed from Xencor
• Extends half-life
• Increases tissue concentration
  VIR-7831VIR-7832VIR-3434VIR-2482

XX2 vaccinal

mutation

• Licensed from Rockefeller University
• Increases potency
• Induces T-cell protection

VIR-7832

VIR-3434

© 2021 Vir Biotechnology, Inc.

5